MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • White Papers
  • DeviceTalks
Home » Miracor closes $30m Series D

Miracor closes $30m Series D

January 4, 2018 By Fink Densford Leave a Comment

Share

Miracor Medical

Miracor Medical Systems said today it closed a $30.2 million (EU €25 million) round of funding as part of Series D financing round with funds slated to support further development and commercialization of its PiCSO impulse system, and announced it is moving its headquarters from Austria to Belgium.

The company’s PiCSO therapy is designed to be used during stenting procedures for patients affected by acute myocardial infarcts to improve pressure in the coronary venous system to improve microcirculatory flow and improve perfusion in the infarcted area.

The round was led by Shenzhen, China-based Ming Capital and co-led by a strategic investor and joined by newly invested SFPI, SRIW and Meusinvest and existing investors Earlybird Venture Capital, Delta Partners, SHS Gesellschaft für Beteiligungsmanagement, Biomed Invest and Peppermint Venture Partners.

“Miracor Medical has shown that the PiCSO Impulse System may reduce infarct size and improve cardiac function. We are impressed with the company’s performance and the latest clinical data on the PiCSO Impulse System, which show statistically significant better results for PiCSO-treated patients in a propensity score matched control. PiCSO has global potential and we look forward to supporting and partnering with Miracor Medical to improve the outcomes of patients following acute infarcts and bring the PiCSO Impulse System to the next stage of clinical development,” Ming Capital managing partner Jack Yang said in a press release.

As part of the financing round, whicn included both equity and debt and a non-dilutive cash advance from Wallonia’s government, the company said it is relocating its headquarters to Belgium.

“I am very excited by the prospects for the company. The funds will allow us to run a randomized clinical trial in Europe, work with FDA to get approval for a large US trial and bring the PiCSO therapy to the market in Europe. I wish to thank all the investors for their trust, especially the Austrian (aws Gründerfonds) and Belgian public investors that allow for this important financing and step towards getting the PiCSO therapy accessible to patients,” Miracor CEO Olivier Delporte said in a prepared statement.

Filed Under: Business/Financial News, Cardiovascular Tagged With: Miracor

In case you missed it

  • Mevion wins FDA 510(k) for S250i proton therapy system
  • Miracor closes $30m Series D
  • Accuray pulls the trigger on Series A convertible senior note buyback
  • Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
  • AngioDynamics shares fall on Q2 sales miss
  • Abbott nabs CMS reimbursement for FreeStyle Libre continuous glucose monitor
  • Zimmer Biomet wins FDA nod for Sidus stem-free shoulder system
  • Penumbra, Sixense launch VR JV MVI Health
  • Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
  • Malaysian regulators extend moratorium to summer 2018 for qualifying medical device registrants
  • Invicta Medical raises $21m for sleep apnea device
  • Hologic wins CE Mark for MyoSure Manual
  • Gore launches FDA IDE Excluder conformable AAA endoprosthesis trial
  • Medical device companies need to worry more about liability: Here’s why
  • Glaukos seeks FDA IDE nod for iStent infinite trial
  • FDA issues Class I recall for select J&J Sterilmed Agilis steerable introducer sheaths
  • Tandem Diabetes Care launches manufacturing ops at new San Diego plant

RSS From Medical Design & Outsourcing

  • Malaysian regulators extend moratorium to summer 2018 for qualifying medical device registrants
    By Stewart Eisenhart, Emergo Group The Medical Device Authority (MDA), Malaysia’s medical device regulator, will extend a moratorium for companies that have registered for market access but not yet received approval so that they may continue selling in the country as their premarket reviews proceed. Get the full story here at the Emergo Group’s blog. […]
  • Medical device companies need to worry more about liability: Here’s why
    Mike Drues has a piece of advice he likes to repeat to clients of his medical device regulatory consulting business: Don’t fear FDA; fear the product liability attorneys. “You should fear the product liability attorneys because they could impose a heck of a lot more damage on a company than the FDA ever could. And by […]
  • Why innovation isn’t the key for treating stroke
    Technology and innovation are not the most important things we can do for stroke, according to Stacey Pugh, VP and general manager of the neurovascular unit at Medtronic. The most important thing that could happen for stroke is passing proper legislation about taking patients in emergency situations to comprehensive stroke centers for proper treatment, Pugh […]
  • These lab-grown blood vessel replacements could benefit dialysis patients
    University of Minnesota researchers have developed a blood vessel replacement made of biological materials in a lab. The lab-grown vessels have no living cells at implantation and could be used as a graft for kidney dialysis patients. The lab-engineered blood vessel replacement is the first non synthetic, decellularized graft that is repopulated with cells using […]
  • Medical Device Excise Tax set to return early this year
    By Stewart Eisenhart, Emergo Group Despite multi-year efforts to fully repeal the Medical Device Excise Tax (MDET) on device sales in the US, the tax appears set to come back into force in early 2018. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s […]
  • Webinar: The top medtech stories of 2017 – Jan. 30
    Tuesday, January 30, 2018 2:00pm ET / 11:00 PT     The medtech industry saw its transformation accelerate in 2017: Whether it’s the roster of largest companies, business models or the regulatory environment, times are a-changing. Competition is also heating up in areas including diabetes care and robotic surgery. MDO’s managing editor Chris Newmarker will […]
  • Report slams European Union’s high-risk medical device approvals rate
    A health economics and outcomes research group has concluded that the assessment for high-risk medical devices in the European Union is of low quality and needs improvement. The report appears in the December 2017 issue of Value in Health by ISPOR. The authors looked at 1,376 health technology assessment (HTA) reports filed between 2010 and 2015. […]
  • Victrex opens $13 million Polymer Innovation Center
    Victrex recently announced that it has opened its new $13 million Polymer Innovation Center in Thornton Cleveleys, U.K. to help accelerate innovation. Victrex currently makes high-performance polyaryletherketone (PAEK) as well as selected parts for gears and dental discs. In hopes of developing next-generation thermoplastic solutions, the new facility is fully-operational and is dedicated to research […]
  • Medical device startups: Here’s how you successfully plan
    The development of the product development plan is an evolutionary effort that continues through the life of the medical device project. Bill Betten, Betten Systems Solutions, and Tom Waddell, Waddell Group This is the second in a series of articles that will discuss the design of innovative products in the highly regulated medical environment.  The […]
  • FDA refines least burdensome guidance for medical device oversight
    Stewart Eisenhart, Emergo Group Medical device regulators at the Food and Drug Administration have updated guidance clarifying what Least Burdensome Provisions mean for US market registrants. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MedicalDesignandOutsourcing.com […]
  • The medical device tax is back in effect
    The ringing in of the new year also rang in the return of the medical device tax, a 2.3% levy on medtech sales that went back into effect after a two-year pause. The U.S. Congress closed out 2017 without taking action to delay or repeal the medtech tax, despite broad support from both sides of the […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Connect with us on Google PlusGoogle+

Copyright © 2018 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy